Enhanced innate inflammation induced by anti-btla antibody in dual insult model of hemorrhagic shock/sepsis

Shock

Volumn 45, Issue 1, 2016, Pages 40-49

  Cheng, Tingting ^a   Bai, Jianwen ^a   Chung, Chun Shiang ^b   Chen, Yaping ^b   Biron, Bethany M ^b,c   Ayala, Alfred ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Co inhibitory receptor; dendritic cell; IL 10; macrophage; MODS; recruitment

Indexed keywords

ALANINE AMINOTRANSFERASE; B AND T LYMPHOCYTE ATTENUATOR; B AND T LYMPHOCYTE ATTENUATOR ANTIBODY; CXCL3 CHEMOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BTLA PROTEIN, MOUSE; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; HEMORRHAGIC SHOCK; IMMUNOCOMPETENT CELL; INFLAMMATION; LEUKOCYTE COUNT; MACROPHAGE; MALE; MORBIDITY; MORTALITY; MOUSE; NEUTROPHIL COUNT; NONHUMAN; ORGAN INJURY; PERITONEUM MACROPHAGE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEPSIS; SURVIVAL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; COMPLICATION; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; INNATE IMMUNITY; LEUKOCYTE; MICROBIOLOGY; PERITONEAL CAVITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL LOAD; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNITY, INNATE; INFLAMMATION; LEUKOCYTES; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE, INBRED C57BL; PERITONEAL CAVITY; RECEPTORS, IMMUNOLOGIC; SEPSIS; SHOCK, HEMORRHAGIC;

EID: 84952308846     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000479     Document Type: Article

References (42)

1. Ertel W, Morrison MH, Ayala A, Dean RE, Chaudry IH: Interferon-gamma attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery 111:177-187, 1992.
2. Zervos EE, Kramer AA, Salhab KF, Norman JG, Carey LC, Rosemurgy AS: Sublethal hemorrhage blunts the inflammatory cytokine response to endotoxin in a rat model. J Trauma 46:145-149, 1999.
3. Flohé S, Ackermann M, Reuter M, Nast-Kolb D, Schade FU: Sublethal hemorrhagic shock reduces tumor necrosis factor-Alpha-producing capacity in different cell compartments. Eur Cytokine Netw 11:420-426, 2000.
4. Schröder J, Kahlke V, Fändrich F, Zabel P, Kremer B: Tumor necrosis factoralpha hyporesponsiveness of rat intestinal mononuclear cells and whole portal venous blood after hemorrhagic shock. Crit Care Med 26:526-532, 1998.
5. Goris RJ: Multiple organ failure: whole body inflammation? Schweiz Med Wochenschr 119:347-353, 1989.
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
7. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813-822, 2006.
8. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862-874, 2013.
9. Tamayo E, Gómez E, Bustamante J, Gómez-Herreras JI, Fonteriz R, Bobillo F, Bermejo-Martín JF, Castrodeza J, Heredia M, Fierro I, et al.: Evolution of neutrophil apoptosis in septic shock survivors and nonsurvivors. J Crit Care 27:415.e1-e11, 2012.
10. Drifte G, Dunn-Siegrist I, Tissières P, Pugin J: Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med 41:820-832, 2013.
11. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung C-S, et al.: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 106:6303-6308, 2009.
12. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS: Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88:233-240, 2010.
13. Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS: Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36:38-44, 2011.
14. Murphy TL, Murphy KM: Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol 28:389-411, 2010.
15. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, et al.: B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6:90-98, 2005.
16. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM: Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 312:1236-1243, 2003.
17. Shui J-W, Steinberg MW, Kronenberg M: Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol 89:517-523, 2011.
18. Hurchla MA, Sedy JR, Murphy KM: Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 178:6073-6082, 2007.
19. Cheung TC, SteinbergMW, Oborne LM, Macauley MG, Fukuyama S, Sanjo H, DSouza C, Norris PS, Pfeffer K, Murphy KM, et al.: Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci U S A 106:6244-6249, 2009.
20. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A: BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 92:593-603, 2012.
21. Adler G, Steeg C, Pfeffer K, Murphy TL, Murphy KM, Langhorne J, Jacobs T: B and T lymphocyte attenuator restricts the protective immune response against experimental malaria. J Immunol 187:5310-5319, 2011.
22. Lepenies B, Pfeffer K, Hurchla MA, Murphy TL, Murphy KM, Oetzel J, Fleischer B, Jacobs T: Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J Immunol 179:4093-4100, 2007.
23. Crawford A, Wherry EJ: Editorial: Therapeutic potential of targeting BTLA. J Leukoc Biol 86:5-8, 2009.
24. Tang L, Bai J, Chung C-S, Lomas-Neira J, Chen Y, Huang X, Ayala A: Programmed cell death receptor ligand 1 modulates the regulatory T cells capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1. Shock 43:47-54, 2015.
25. Bai J, Tang L, Lomas-Neira J, Chen Y, McLeish KR, Uriarte SM, Chung C-S, Ayala A: TAT-SNAP-23 treatment inhibits the priming of neutrophil functions contributing to shock and/or sepsis-induced extra-pulmonary acute lung injury. Innate Immun 21:42-54, 2015.
26. Lomas-Neira JL, Chung C-S, Grutkoski PS, Miller EJ, Ayala A: CXCR2 inhibition suppresses hemorrhage-induced priming for acute lung injury in mice. J Leukoc Biol 76:58-64, 2004.
27. Kobayashi Y, Iwata A, Suzuki K, Suto A, Kawashima S, Saito Y, Owada T, Kobayashi M, Watanabe N, Nakajima H: B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells. Proc Natl Acad Sci U S A 110:5121-5126, 2013.
28. Perl M, Chung C-S, Perl U, Lomas-Neira J, de Paepe M, Cioffi WG, Ayala A: Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. Am J Respir Crit Care Med 176:591-601, 2007.
29. Vermes I, Haanen C, Steffens-Nakken H, Reutelings perger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39-51, 1995.
30. Davalos-Misslitz ACM, Rieckenberg J, Willenzon S, Worbs T, Kremmer E, Bernhardt G, Förster R: Generalized multi-organ autoimmunity in CCR7-deficient mice. Eur J Immunol 37:613-622, 2007.
31. Young DS, Pestaner LC, Gibberman V: Effects of drugs on clinical laboratory tests. Clin Chem 21:1D-432D, 1975.
32. Jin L, Batra S, Douda DN, Palaniyar N, Jeyaseelan S: CXCL1 contributes to host defense in polymicrobial sepsis via modulating T cell and neutrophil functions. J Immunol 193:3549-3558, 2014.
33. Weber GF, Swirski FK: Immunopathogenesis of abdominal sepsis. Langenbecks Arch Surg 399:1-9, 2014.
34. Naiki Y, Michelsen KS, Schröder NWJ, Alsabeh R, Slepenkin A, Zhang W, Chen S, Wei B, Bulut Y, Wong MH, et al.: MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem 280:29242-29249, 2005.
35. Sun Y, Brown NK, Ruddy MJ, Miller ML, Lee Y, Wang Y, Murphy KM, Pfeffer K, Chen L, Kaye J, et al.: B and T lymphocyte attenuator tempers early infection immunity. J Immunol 183:1946-1951, 2009.
36. Vincent J-L, Nelson DR, Williams MD: Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med 39:1050-1055, 2011.
37. Shubin NJ, Monaghan SF, Heffernan DS, Chung C-S, Ayala A: B and T lymphocyte attenuator expression on CD4 T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care 17:R276, 2013.
38. Manes S, Mira E, Gómez-Mouton C, Zhao ZJ, Lacalle RA, Martínez-AC: Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol 19:3125-3135, 1999.
39. Sharma N, Everingham S, Ramdas B, Kapur R, Craig AWB: SHP2 phosphatase promotes mast cell chemotaxis toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis. J Immunol 192:4859-4866, 2014.
40. Yang C, Chen Y, Guo G, Li H, Cao D, Xu H, Guo S, Fei L, YanW, Ning Q, et al.: Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3. Gut 62:1204-1213, 2013.
41. Cai G, Freeman GJ: The CD160, BTLA, LIGHT/HVEM pathway: A bidirectional switch regulating T-cell activation. Immunol Rev 229:244-258, 2009.
42. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al.: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670-679, 2003.